Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responsesNykode’s APC targeted vaccine technology consistently results in faster, broader and stronger immune response compared to non-targeted vaccines, whether delivered as DNA or mRNA OSLO, Norway, Oct. 09, 2023 (GLOBE NEWSWIRE) Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it is p
FDA approval of IND for VB-C-04 trial.Nykode to further elaborate on trial design and development strategy at upcoming capital markets day in New York on.
FDA approval of IND for VB-C-04 trial.Nykode to further elaborate on trial design and development strategy at upcoming capital markets day in New York on September 20. OSLO, Norway, Sept. 05, 2023 (GLOBE NEWSWIRE)
FDA approval of IND for VB-C-04 trial.Nykode to further elaborate on trial design and development strategy at upcoming capital markets day in New York on September 20.